Search for:

Sign in
Register
Country Reports
Interviews
InFocus
Europe
Asia-Pacific
Americas
Middle East & Africa
Legal & Regulatory
Facts & Figures
Library
Op-eds
Shop

Sign In Register

Home
Country Reports
Exclusive interviews
- All
- Latest
- Americas
- Asia-Pacific
- Europe
- Middle East & Africa
Articles
- All
- Global
- Latest
Legal & Regulatory
Op-Eds & Contributions
InFigures
Library
- All
- InFocus
- InFigures
- White Papers
Media Kit
Register
About Us

Country Reports
Interviews
InFocus
Europe
Asia-Pacific
Americas
Middle East & Africa
Legal & Regulatory
Facts & Figures
Library
Op-eds
Shop

written on 25.06.2014

Share on Facebook

Share on Whatsapp

Share on Twitter

Share on Linked in

FDA panel fails to back AZ ovarian cancer drug olaparib

Share on Facebook

Share on Whatsapp

Share on Twitter

Share on Linked in

TAGS: ,

FDA panel fails to back AZ ovarian cancer drug olaparib

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here

Pharmaboardroom

Library
Contributions
China
Singapore
Saudi Arabia
Vaccines
Pharma Updates
Facts & Figures
Directory
Shop

Legal & Privacy

Library
Contributions
China
Singapore
Saudi Arabia
Vaccines
Pharma Updates
Facts & Figures
Directory
Shop

Contact us

+44 2078673717
info@pharmaboardroom.com

For media inquiries, please contact:
media@pharmaboardroom.com

Address:
PharmaBoardroom Limited
Evolution House
Iceni Court, Delft Way,
Norwich, NR6 6BB UK

Subscribe

Email Newsletters

Social Media

Sign in

Forgot password? Register Now